Ceramide Synthase 1 is Regulated by Proteasomal Mediated Turnover

Overview

Journal Biochim Biophys Acta

Specialties Biochemistry
Biophysics

Date 2009 Apr 28

PMID 19393694

Citations 24

Authors

Priya Sridevi

Hannah Alexander

Elad L Laviad

Yael Pewzner-Jung

Mark Hannink

Anthony H Futerman

Stephen Alexander

Affiliations

Soon will be listed here.

Abstract

Ceramide is an important bioactive lipid, intimately involved in many cellular functions, including the regulation of cell death, and in cancer and chemotherapy. Ceramide is synthesized de novo from sphinganine and acyl CoA via a family of 6 ceramide synthase enzymes, each having a unique preference for different fatty acyl CoA substrates and a unique tissue distribution. However, little is known regarding the regulation of these important enzymes. In this study we focus on ceramide synthase 1 (CerS1) which is the most structurally and functionally distinct of the enzymes, and describe a regulatory mechanism that specifically controls the level of CerS1 via ubiquitination and proteasome dependent protein turnover. We show that both endogenous and ectopically expressed CerS1 have rapid basal turnover and that diverse stresses including chemotherapeutic drugs, UV light and DTT can induce CerS1 turnover. The turnover requires CerS1 activity and is regulated by the opposing actions of p38 MAP kinase and protein kinase C (PKC). p38 MAP kinase is a positive regulator of turnover, while PKC is a negative regulator of turnover. CerS1 is phosphorylated in vivo and activation of PKC increases the phosphorylation of the protein. This study reveals a novel and highly specific mechanism by which CerS1 protein levels are regulated and which directly impacts ceramide homeostasis.

Citing Articles

Lipid remodeling in acrosome exocytosis: unraveling key players in the human sperm.

Suhaiman L, Belmonte S Front Cell Dev Biol. 2024; 12:1457638.

PMID: 39376630 PMC: 11456524. DOI: 10.3389/fcell.2024.1457638.

Cannabidiol's cytotoxicity in pancreatic cancer is induced via an upregulation of ceramide synthase 1 and ER stress.

Mangal N, Reebye V, Habib N, Sodergren M J Cannabis Res. 2024; 6(1):22.

PMID: 38720356 PMC: 11077855. DOI: 10.1186/s42238-024-00227-x.

Mysterious sphingolipids: metabolic interrelationships at the center of pathophysiology.

Jamjoum R, Majumder S, Issleny B, Stiban J Front Physiol. 2024; 14:1229108.

PMID: 38235387 PMC: 10791800. DOI: 10.3389/fphys.2023.1229108.

Natural Products and Small Molecules Targeting Cellular Ceramide Metabolism to Enhance Apoptosis in Cancer Cells.

Afrin F, Mateen S, Oman J, Lai J, Barrott J, Pashikanti S Cancers (Basel). 2023; 15(18).

PMID: 37760612 PMC: 10527029. DOI: 10.3390/cancers15184645.

The heat shock protein Hsp27 controls mitochondrial function by modulating ceramide generation.

Boyd R, Majumder S, Stiban J, Mavodza G, Straus A, Kempelingaiah S Cell Rep. 2023; 42(9):113081.

PMID: 37689067 PMC: 10591768. DOI: 10.1016/j.celrep.2023.113081.

References

Baldwin R, Garratt-Lalonde M, Parolin D, Krzyzanowski P, Andrade M, Lorimer I . Protection of glioblastoma cells from cisplatin cytotoxicity via protein kinase Ciota-mediated attenuation of p38 MAP kinase signaling. Oncogene. 2005; 25(20):2909-19. DOI: 10.1038/sj.onc.1209312. View

Modrak D, Gold D, Goldenberg D . Sphingolipid targets in cancer therapy. Mol Cancer Ther. 2006; 5(2):200-8. DOI: 10.1158/1535-7163.MCT-05-0420. View

Baran Y, Salas A, Senkal C, Gunduz U, Bielawski J, Obeid L . Alterations of ceramide/sphingosine 1-phosphate rheostat involved in the regulation of resistance to imatinib-induced apoptosis in K562 human chronic myeloid leukemia cells. J Biol Chem. 2007; 282(15):10922-34. DOI: 10.1074/jbc.M610157200. View

van Meer G, Voelker D, Feigenson G . Membrane lipids: where they are and how they behave. Nat Rev Mol Cell Biol. 2008; 9(2):112-24. PMC: 2642958. DOI: 10.1038/nrm2330. View

Huwiler A, Zangemeister-Wittke U . Targeting the conversion of ceramide to sphingosine 1-phosphate as a novel strategy for cancer therapy. Crit Rev Oncol Hematol. 2007; 63(2):150-9. DOI: 10.1016/j.critrevonc.2007.04.010. View

Mizutani Y, Kihara A, Igarashi Y . LASS3 (longevity assurance homologue 3) is a mainly testis-specific (dihydro)ceramide synthase with relatively broad substrate specificity. Biochem J. 2006; 398(3):531-8. PMC: 1559458. DOI: 10.1042/BJ20060379. View

Mizutani Y, Kihara A, Igarashi Y . Mammalian Lass6 and its related family members regulate synthesis of specific ceramides. Biochem J. 2005; 390(Pt 1):263-71. PMC: 1184580. DOI: 10.1042/BJ20050291. View

Kageyama-Yahara N, Riezman H . Transmembrane topology of ceramide synthase in yeast. Biochem J. 2006; 398(3):585-93. PMC: 1559446. DOI: 10.1042/BJ20060697. View

Pewzner-Jung Y, Ben-Dor S, Futerman A . When do Lasses (longevity assurance genes) become CerS (ceramide synthases)?: Insights into the regulation of ceramide synthesis. J Biol Chem. 2006; 281(35):25001-5. DOI: 10.1074/jbc.R600010200. View

10.

Teufel A, Maass T, Galle P, Malik N . The longevity assurance homologue of yeast lag1 (Lass) gene family (review). Int J Mol Med. 2009; 23(2):135-40. View

11.

Cuvillier O, Pirianov G, Kleuser B, Vanek P, Coso O, Gutkind S . Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. Nature. 1996; 381(6585):800-3. DOI: 10.1038/381800a0. View

12.

Riebeling C, Allegood J, Wang E, Merrill Jr A, Futerman A . Two mammalian longevity assurance gene (LAG1) family members, trh1 and trh4, regulate dihydroceramide synthesis using different fatty acyl-CoA donors. J Biol Chem. 2003; 278(44):43452-9. DOI: 10.1074/jbc.M307104200. View

13.

Koybasi S, Senkal C, Sundararaj K, Spassieva S, Bielawski J, Osta W . Defects in cell growth regulation by C18:0-ceramide and longevity assurance gene 1 in human head and neck squamous cell carcinomas. J Biol Chem. 2004; 279(43):44311-9. DOI: 10.1074/jbc.M406920200. View

14.

Laviad E, Albee L, Pankova-Kholmyansky I, Epstein S, Park H, Merrill Jr A . Characterization of ceramide synthase 2: tissue distribution, substrate specificity, and inhibition by sphingosine 1-phosphate. J Biol Chem. 2008; 283(9):5677-84. DOI: 10.1074/jbc.M707386200. View

15.

Conklin K . Chemotherapy-associated oxidative stress: impact on chemotherapeutic effectiveness. Integr Cancer Ther. 2004; 3(4):294-300. DOI: 10.1177/1534735404270335. View

16.

Choi B, Hur E, Lee J, Jun D, Kim K . Protein kinase Cdelta-mediated proteasomal degradation of MAP kinase phosphatase-1 contributes to glutamate-induced neuronal cell death. J Cell Sci. 2006; 119(Pt 7):1329-40. DOI: 10.1242/jcs.02837. View

17.

Wang X, Martindale J, Holbrook N . Requirement for ERK activation in cisplatin-induced apoptosis. J Biol Chem. 2000; 275(50):39435-43. DOI: 10.1074/jbc.M004583200. View

18.

Shi R, Ong C, Shen H . Protein kinase C inhibition and x-linked inhibitor of apoptosis protein degradation contribute to the sensitization effect of luteolin on tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in cancer cells. Cancer Res. 2005; 65(17):7815-23. DOI: 10.1158/0008-5472.CAN-04-3875. View

19.

Hannun Y, Obeid L . Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol. 2008; 9(2):139-50. DOI: 10.1038/nrm2329. View

20.

Min J, Mesika A, Sivaguru M, Van Veldhoven P, Alexander H, Futerman A . (Dihydro)ceramide synthase 1 regulated sensitivity to cisplatin is associated with the activation of p38 mitogen-activated protein kinase and is abrogated by sphingosine kinase 1. Mol Cancer Res. 2007; 5(8):801-12. DOI: 10.1158/1541-7786.MCR-07-0100. View